Abstract
Deposition of amyloid-β (Aβ) peptides in the brain is a central event in the pathogenesis of Alzheimer’s disease (AD), which makes Aβ peptides a crucial target for therapeutic intervention. Significant efforts have been made towards the development of ligands that bind to Aβ peptides with a goal of early detection of amyloid aggregation and the neutralization of Aβ toxicity. Short single-stranded oligonucleotide aptamers bind with high affinity and specificity to their targets. Aptamers that specifically bind to Aβ monomers, specifically the 40 and 42 amino acid species (Aβ1-40 and Aβ1- 42), fibrils and plaques have a great potential for diagnostic applications and the treatment of AD. Herein, we review the aptamers that bind to the various forms of Aβ peptides for use in diagnosis and to inhibit plaque formation.
Keywords: Alzheimer's disease, Beta-amyloid, Aptamer, Oligonucleotide, SELEX
Current Alzheimer Research
Title:Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer’s Disease Pathology
Volume: 10 Issue: 4
Author(s): Rudi K. Tannenberg, Hadi Al. Shamaileh, Lasse H. Lauridsen, Jagat R. Kanwar, Peter R. Dodd and Rakesh N. Veedu
Affiliation:
Keywords: Alzheimer's disease, Beta-amyloid, Aptamer, Oligonucleotide, SELEX
Abstract: Deposition of amyloid-β (Aβ) peptides in the brain is a central event in the pathogenesis of Alzheimer’s disease (AD), which makes Aβ peptides a crucial target for therapeutic intervention. Significant efforts have been made towards the development of ligands that bind to Aβ peptides with a goal of early detection of amyloid aggregation and the neutralization of Aβ toxicity. Short single-stranded oligonucleotide aptamers bind with high affinity and specificity to their targets. Aptamers that specifically bind to Aβ monomers, specifically the 40 and 42 amino acid species (Aβ1-40 and Aβ1- 42), fibrils and plaques have a great potential for diagnostic applications and the treatment of AD. Herein, we review the aptamers that bind to the various forms of Aβ peptides for use in diagnosis and to inhibit plaque formation.
Export Options
About this article
Cite this article as:
K. Tannenberg Rudi, Al. Shamaileh Hadi, H. Lauridsen Lasse, R. Kanwar Jagat, R. Dodd Peter and N. Veedu Rakesh, Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer’s Disease Pathology, Current Alzheimer Research 2013; 10 (4) . https://dx.doi.org/10.2174/1567205011310040009
DOI https://dx.doi.org/10.2174/1567205011310040009 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry Possible Considerations for the Management of Turcot’s Syndrome?
Current Cancer Therapy Reviews Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?
Current Cancer Therapy Reviews Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide
Reviews on Recent Clinical Trials Separation of Ginseng Active Ingredients and their Roles in Cancer Metastasis Supplementary Therapy
Current Drug Metabolism MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells
MicroRNA Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design Comparison of Anticancer Properties of Annona muricata L. Acetonic and Methanolic Leaf Extracts
The Natural Products Journal Angiomodulatory and Neurological Effects of Ginsenosides
Current Medicinal Chemistry Exploring siRNA Umpired Nanogels: A Tale of Barrier Combating Carrier
Current Pharmaceutical Design Genomic Signatures for Individualized Treatment of Malignant Tumors
Current Drug Discovery Technologies STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets